The activated PI3K/Akt/mTOR pathway has been shown to decrease the BH3 (Bcl-2 homology domain) mimetic effectiveness in cancer cells by upregulating anti-apoptotic Bcl-2 family members, such as Mcl-1 [61]. The gene discussed is PIK3CD; the disease is cancer.